A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

被引:1003
作者
Shi, Rui [1 ,2 ]
Shan, Chao [3 ]
Duan, Xiaomin [1 ,2 ]
Chen, Zhihai [4 ]
Liu, Peipei [5 ]
Song, Jinwen [6 ]
Song, Tao [1 ,7 ,8 ]
Bi, Xiaoshan [1 ,9 ]
Han, Chao [1 ,2 ]
Wu, Lianao [9 ,10 ]
Gao, Ge [3 ]
Hu, Xue [3 ]
Zhang, Yanan [3 ]
Tong, Zhou [1 ,10 ]
Huang, Weijin [11 ]
Liu, William Jun [5 ]
Wu, Guizhen [5 ]
Zhang, Bo [3 ]
Wang, Lan [11 ]
Qi, Jianxun [10 ,12 ]
Feng, Hui [13 ]
Wang, Fu-Sheng [6 ]
Wang, Qihui [1 ,10 ,12 ]
Gao, George Fu [10 ]
Yuan, Zhiming [3 ]
Yan, Jinghua [1 ,10 ,12 ]
机构
[1] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Microbial Physiol & Metab Engn, Beijing, Peoples R China
[2] Univ Chinese Acad Sci, Beijing, Peoples R China
[3] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, Wuhan, Peoples R China
[4] Capital Med Univ, Beijing Ditan Hosp, Ctr Infect Dis, Beijing, Peoples R China
[5] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing, Peoples R China
[6] Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Infect Dis, Med Ctr 5, Treatment & Res Ctr Infect Dis, Beijing, Peoples R China
[7] Shanxi Acad Adv Res & Innovat, Taiyuan, Peoples R China
[8] Hebei Normal Univ Sci & Technol, Coll Anim Sci & Technol, Qinhuangdao, Hebei, Peoples R China
[9] Anhui Univ, Inst Phys Sci & Informat, Hefei, Peoples R China
[10] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China
[11] Natl Inst Food & Drug Control, Minist Hlth Res Qual & Standardizat Biotech Prod, Key Lab, Beijing, Peoples R China
[12] Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China
[13] Shanghai Junshi Biosci Co Ltd, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
SARS-COV; SPIKE PROTEIN; CORONAVIRUS; FEATURES;
D O I
10.1038/s41586-020-2381-y
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
An outbreak of coronavirus disease 2019 (COVID-19)(1-3), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(4), has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus-receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic. Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2-receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.
引用
收藏
页码:120 / +
页数:16
相关论文
共 31 条
  • [1] PHENIX: a comprehensive Python']Python-based system for macromolecular structure solution
    Adams, Paul D.
    Afonine, Pavel V.
    Bunkoczi, Gabor
    Chen, Vincent B.
    Davis, Ian W.
    Echols, Nathaniel
    Headd, Jeffrey J.
    Hung, Li-Wei
    Kapral, Gary J.
    Grosse-Kunstleve, Ralf W.
    McCoy, Airlie J.
    Moriarty, Nigel W.
    Oeffner, Robert
    Read, Randy J.
    Richardson, David C.
    Richardson, Jane S.
    Terwilliger, Thomas C.
    Zwart, Peter H.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 : 213 - 221
  • [2] Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
    Channappanavar, Rudragouda
    Fehr, Anthony R.
    Vijay, Rahul
    Mack, Matthias
    Zhao, Jincun
    Meyerholz, David K.
    Perlman, Stanley
    [J]. CELL HOST & MICROBE, 2016, 19 (02) : 181 - 193
  • [3] MolProbity: all-atom structure validation for macromolecular crystallography
    Chen, Vincent B.
    Arendall, W. Bryan, III
    Headd, Jeffrey J.
    Keedy, Daniel A.
    Immormino, Robert M.
    Kapral, Gary J.
    Murray, Laura W.
    Richardson, Jane S.
    Richardson, David C.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 : 12 - 21
  • [4] Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
    Corti, Davide
    Misasi, John
    Mulangu, Sabue
    Stanley, Daphne A.
    Kanekiyo, Masaru
    Wollen, Suzanne
    Ploquin, Aurelie
    Doria-Rose, Nicole A.
    Staupe, Ryan P.
    Bailey, Michael
    Shi, Wei
    Choe, Misook
    Marcus, Hadar
    Thompson, Emily A.
    Cagigi, Alberto
    Silacci, Chiara
    Fernandez-Rodriguez, Blanca
    Perez, Laurent
    Sallusto, Federica
    Vanzetta, Fabrizia
    Agatic, Gloria
    Cameroni, Elisabetta
    Kisalu, Neville
    Gordon, Ingelise
    Ledgerwood, Julie E.
    Mascola, John R.
    Graham, Barney S.
    Muyembe-Tamfun, Jean-Jacques
    Trefry, John C.
    Lanzavecchia, Antonio
    Sullivan, Nancy J.
    [J]. SCIENCE, 2016, 351 (6279) : 1339 - 1342
  • [5] Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
    Du, Lanying
    Zhang, Xiujuan
    Liu, Jixiang
    Jiang, Shibo
    [J]. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2011, (51):
  • [6] The spike protein of SARS-CoV - a target for vaccine and therapeutic development
    Du, Lanying
    He, Yuxian
    Zhou, Yusen
    Liu, Shuwen
    Zheng, Bo-Jian
    Jiang, Shibo
    [J]. NATURE REVIEWS MICROBIOLOGY, 2009, 7 (03) : 226 - 236
  • [7] Features and development of Coot
    Emsley, P.
    Lohkamp, B.
    Scott, W. G.
    Cowtan, K.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2010, 66 : 486 - 501
  • [8] From "A'' IV to "Z''IKV: Attacks from Emerging and Re-emerging Pathogens
    Gao, George F.
    [J]. CELL, 2018, 172 (06) : 1157 - 1159
  • [9] Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
    Gaudinski, Martin R.
    Coates, Emily E.
    Novik, Laura
    Widge, Alicia
    Houser, Katherine V.
    Burch, Eugeania
    Holman, LaSonji A.
    Gordon, Ingelise J.
    Chen, Grace L.
    Carter, Cristina
    Nason, Martha
    Sitar, Sandra
    Yamshchikov, Galina
    Berkowitz, Nina
    Andrews, Charla
    Vazquez, Sandra
    Laurencot, Carolyn
    Misasi, John
    Arnold, Frank
    Carlton, Kevin
    Lawlor, Heather
    Gall, Jason
    Bailer, Robert T.
    McDermott, Adrian
    Capparelli, Edmund
    Koup, Richard A.
    Mascola, John R.
    Graham, Barney S.
    Sullivan, Nancy J.
    Ledgerwood, Julie E.
    [J]. LANCET, 2019, 393 (10174) : 889 - 898
  • [10] The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
    Gorbalenya, Alexander E.
    Baker, Susan C.
    Baric, Ralph S.
    de Groot, Raoul J.
    Drosten, Christian
    Gulyaeva, Anastasia A.
    Haagmans, Bart L.
    Lauber, Chris
    Leontovich, Andrey M.
    Neuman, Benjamin W.
    Penzar, Dmitry
    Perlman, Stanley
    Poon, Leo L. M.
    Samborskiy, Dmitry V.
    Sidorov, Igor A.
    Sola, Isabel
    Ziebuhr, John
    [J]. NATURE MICROBIOLOGY, 2020, 5 (04) : 536 - 544